Compare CRMT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | LGVN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.8M |
| IPO Year | 2026 | 2021 |
| Metric | CRMT | LGVN |
|---|---|---|
| Price | $0.72 | $1.66 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | $7.50 | ★ $61.25 |
| AVG Volume (30 Days) | ★ 522.1K | 84.9K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | $1.29 | $24.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.48 |
| 52 Week High | $28.70 | $7.60 |
| Indicator | CRMT | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 41.72 |
| Support Level | $0.57 | $0.65 |
| Resistance Level | $1.49 | $1.86 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.74 | 4.21 |
America's Car-Mart Inc is one of the publicly held automotive retailers in the United States focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The Company mainly sells older model used vehicles and provides financing for substantially all of its customers. The company operates in the Integrated Auto Sales and Finance segment of the used car market. In this industry, the nature of the sale and the financing of the transaction, financing processes, the type of customer and the methods used to distribute the company's products and services, including the actual servicing of the contracts as well as the regulatory environment in which the company operates, all have similar characteristics. The company operates in a single reportable segment.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.